In this episode, Professor Birgitte Regenberg interviews Professor Paul Mischel from Stanford University on his life as a cancer researcher and how circular DNA plays a role in cancer.
In this episode we will be talking about how Paul Mischel got into his field of research and answer a number of questions like, why are certain cancers rapidly adapting to chemotherapy treatments? How has the field of molecular biology changed cancer research? Why is circular DNA important to ongoing cancer research? How do you bring new research to market where it can benefit the patients? And finally, how can research like the kind performed in the CIRCULAR VISION project come to benefit cancer patients in the future?
Part 1 – Why is circular DNA central to cancer research?
Part 2 – Why can cancers quickly develop resistance to treatments?
Part 3 – How can fundamental research be commercialized to benefit patients?
Professor Paul Mischel MD of Stanford University is a physician scientist trained in pathology and cancer biology. He is Vice Chair of Research for the Department of Pathology as well as an Institute Scholar of ChEM-H at Stanford that also studies the role of circular DNA in cancer.
See more about Professor Paul Mischel at Stanford University, Boundless Bio and X (Twitter).
Professor Professor Birgitte Regenberg of Copenhagen University is a pioneer and expert in the field of extrachromosomal circular DNA (eccDNA) and is the coordinator of the CIRCULAR VISION project researching circular DNA as a biomarker in cancer and IBD.
See more about Birgitte Regenberg at Copenhagen University, Regenberg Lab and X (Twitter).
